Skip to content
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
Insights
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Evolving Psychedelic Paradigm
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
JCP Podcast
Rounds in the General Hospital
View All
James L. Karagianis, MD, FRCPC
JCP
Letter to the Editor
Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.
January 15, 2005
James L. Karagianis
,
Eduardo Dunayevich
JCP
Letter to the Editor
Reply to "Possible Impact of Dropout in a Study ofHigh-Dose Olanzapine and Prolactin Levels"
August 16, 2004
James L. Karagianis
,
Anton Baksh
JCP
Original Research
High-Dose Olanzapine and Prolactin Levels
October 15, 2003
James L. Karagianis
,
Anton Baksh
JCP
Article
Rapid Tranquilization With Olanzapine in Acute Psychosis: A Case Series
February 1, 2001
James L. Karagianis
,
Ian C. Dawe
,
Joel Raskin
, et al
